Key facts
- Notable investors include Beijing Xietong Chuangxin Holding, Guangdong Academy of Greater Bay Area Studies, Heying Asset Management.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Delifului
- ·The full record, as it builds
Funding rounds
No funding rounds for Delifului are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Delifului
Developer of drug-delivery systems intended for pharmaceutical companies. The company's research and development direction is closely centered on clinical pain points, and its research and development pipeline covers a wide range of important indications, including anti-tumor, cardiovascular, cerebrovascular, anti-fungal, and postoperative analgesia, enabling clients' drug delivery processes to improve drug efficacy and reduce toxic side effects.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2010
- Website
- bj-delivery.cn/
- Ownership
- Privately Held (backing)
Delifului doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Delifului shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Delifului in its N-PORT filings yet. We sweep new filings monthly.